|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
REVIEW ARTICLE
From the Division of Infectious Disease, The
Children's Hospital, Boston, MA.
The innate immune system provides rapid and effective host defense
against microbial invasion in a manner that is independent of prior
exposure to a given pathogen.1 It has long been
appreciated that the blood contains important elements that mediate
rapid responses to infection. Thus, anatomic compartments with ample
blood supply are less frequently infected and recover more readily once
infected, whereas regions with poor perfusion are prone to severe
infection and may require surgical débridement. Blood-borne
innate immune mediators are either carried in circulating blood cells
(ie, leukocytes and platelets) or in plasma after release from blood
cells or on secretion by the liver.
(Blood. 2000;96:2664-2672) A growing body of research has revealed the
mechanisms by which blood cells exert microbicidal activity. Activated
neutrophils, eosinophils, macrophages, and, to a more limited extent,
lymphocytes increase oxygen consumption during phagocytosis in what has
been termed the "respiratory burst." This oxidative response is now known to be mediated by a multicomponent leukocyte oxidase that transfers electrons to molecular oxygen.2 These oxygen
radicals are converted to hydrogen peroxide and, by the action of
myeloperoxidase, to hypochlorous acid Nitric oxide is another small, rapidly diffusable antimicrobial
mediator, whose production by inducible nitric oxide synthase (iNOS)
contributes to mammalian host defense against intracellular pathogens.5 Although most readily demonstrable in murine
macrophages, iNOS expression and function have been detected in human
macrophages derived from patients with infection or inflammatory
disorders5 as well as in human neutrophils
activated by bacterial infection.6
Studies of murine macrophages have identified the natural
resistance-associated macrophage protein (NRAMP) as an important mediator of innate defense against certain intracellular pathogens (eg, Salmonella, Mycobacteria, and
Leshmania).7 Based on homology to proteins of known
function as well as direct experimental evidence, it has been argued
that NRAMP modulates ion flux across the phagolysosomal membrane.8 Genetic polymorphism of the NRAMP1
gene has been associated with variable human susceptibility to
mycobacterial infections.9
Several observations have suggested that eukaryotic organisms also use
peptide-based oxygen-independent antimicrobial mechanisms. Both leukocytes from patients with CGD and normal leukocytes deprived of oxygen in vitro are capable of killing a variety of
microorganisms.10 Moreover, crude acid extracts of
leukocytes possess direct microbicidal activity that is oxygen
independent.11 Over the past 20 years, a growing number of
cationic proteins and peptides with direct microbicidal activity
demonstrable in vitro have been isolated and
characterized.12 It is increasingly appreciated that an important mechanism by which blood exerts antimicrobial activity is by
the mobilization of these cytotoxic proteins and peptides to
sites of infection. With few exceptions, cell-associated
agents are carried in the cytosolic granules of leukocytes and
platelets, whereas extracellular agents are either the product of
cellular degranulation or of secretion from the liver into acute-phase plasma. In addition to direct microbicidal activity, many of these agents are also capable of neutralizing the proinflammatory effects of
microbial surface components.13-15
The neutrophil granule antibiotics are generally membrane-active
cationic proteins and peptides whose affinity for the negatively charged microbial surface depends not only on electrostatic
interactions but also on their tertiary (3-dimensional) structure.
Despite having similar net positive charge, these agents vary markedly in size, structure, and mechanisms of action, as well as in the selectivity of their cytotoxic effects. Antimicrobial proteins and
peptides often demonstrate relative selectivity toward microbial cells,
which has been attributed to their relatively higher affinity for the
surface lipids of microbial as opposed to eukaryotic
cells.16,17 Although the focus of this review is on the
antimicrobial properties of such cytotoxic proteins and peptides, many
of these agents manifest additional activities relating to immune
modulation and wound healing.12 Similar proteins and
peptides have also been identified in mucosal epithelial
cells.18
Although the focus of this review is on the antimicrobial proteins
and peptides of mammalian blood, it is instructive to consider the
strong similarities of this arm of the innate immune system to
corresponding mediators of nonmammalian vertebrate and invertebrate animals as well as plants. The expression of antimicrobial proteins and
peptides in highly divergent species reflects the common need of
multicellular organisms to defend against microbial invasion (Table
1).19,20 In particular,
great progress has been made in characterizing the innate responses of
insects to infection and septic injury.19-21 Innate
responses to microbial surface components by both insects and mammals
are mediated by structurally homologous signaling molecules, including
Toll-like receptors (TLRs), cytosolic kinases, nuclear factor (NF)- Neutrophils
Lactoferrin. A member of the transferrin family of iron-binding proteins, lactoferrin is an 80-kd protein with 2 iron-binding sites arranged in a bilobed structure.31 Lactoferrin is localized in the secondary granules of neutrophils as well as tear fluid, saliva, and breast milk. In addition to depriving microorganisms of an essential nutrient by binding iron,32 lactoferrin can also exert a directly microbicidal effect, presumably via membrane disruption.33 Lactoferricin is a naturally occurring non-iron-binding microbicidal peptide derived from the N-terminus of lactoferrin.34 Several studies have also documented antiviral effects of lactoferrin against multiple viral pathogens including human immunodeficiency virus.35 In addition to its antibacterial properties, lactoferrin has also been shown to bind to the lipid A moiety of gram-negative bacterial lipopolysaccharide (LPS) thereby neutralizing its endotoxic activity. However, the endotoxin-neutralizing properties of lactoferrin are limited in the presence of the plasma lipopolysaccharide-binding protein (LBP),36 an activator of endotoxic activity that delivers LPS to the macrophage CD14/TLR.37 Nevertheless, lactoferrin administered orally is apparently capable of reducing mortality in a porcine endotoxin shock model.38Bactericidal/permeability-increasing protein (BPI).
The 55-kd BPI selectively exerts multiple activities against
gram-negative bacteria: (1) cytotoxicity, via sequential effects on
outer and inner lipid membranes, (2) opsonization to enhance phagocytosis by neutrophils, and (3) neutralization of gram-negative bacterial LPS or endotoxin.39 The crystal structure of BPI
reveals a symmetric bipartite structure characterized by N- and
C-terminal regions each of which contain lipid-binding apolar
pockets40 (Figure 2). Whereas
the N-terminal region of BPI is highly cationic and contains both
antibacterial and endotoxin-neutralizing properties, its C-terminal end
contributes to the ability of BPI to opsonize gram-negative
bacteria.41
Bactericidal/permeability-increasing protein is bactericidal at nanomolar concentrations toward certain species of gram-negative bacteria (eg, the serum-resistant encapsulated clinical isolate Escherichia coli K1/r but not certain isolates of Serratia marcesens or Enterobacter cloaceae42). The selectivity of the action of BPI toward gram-negative bacteria has been attributed to its high affinity (nmol/L) for the lipid A moiety of LPS (or "endotoxin").43 Studies of the effects of BPI on the biophysical properties of model membranes composed of LPS or phosphatidylglycerol suggest that intercalation of BPI into membrane lipids by interaction with lipid phosphate groups and acyl chains perturbs higher order lipid structure leading to outer and inner membrane lysis.44,45 Gram-negative bacteria with longer LPS chain length are more resistant to BPI action, presumably due to steric hindrance of BPI penetration to target site(s).46 Although BPI is active against membrane vesicles and L-forms of both gram-negative and gram-positive bacteria, the cell walls of gram-positive bacteria render these organisms refractory to the antibacterial activity of BPI.47 Activity of BPI is manifest not only in artificial laboratory media, but also in blood, plasma, and serum. Activated neutrophils release BPI into inflammatory fluids where it is potently bactericidal. BPI acts in synergy with the members of the cathelicidin and defensin peptide families (discussed below) as well as the complement system.48 Addition of a neutralizing anti-BPI serum blocks the bactericidal activity of rabbit inflammatory (ascitic) fluid against encapsulated gram-negative bacteria suggesting that such activity is BPI dependent.49 The ability of BPI to potently inhibit endotoxin of isolated LPS (regardless of chemotype) and of whole bacteria (including strains resistant to the antibacterial action of BPI42,50) is opposite to that of its structural homolog the LBP, which is an acute-phase reactant that greatly amplifies LPS proinflammatory signaling.51 Whereas LBP disaggregates LPS, delivering LPS monomers to the cellular CD14/TLR complex, BPI enhances LPS aggregation, thereby preventing LBP action.52 Although multiple cationic proteins and peptides have demonstrated anti-endotoxic activity when tested in artificial media in vitro,15 BPI is notable for its ability to neutralize endotoxin in biologic fluids even in the presence of LBP,53 suggesting that BPI may contribute to down-regulating the proinflammatory effects of gram-negative bacteria and endotoxin in vivo. Serprocidins. The serprocidins are 25- to 37-kd serine proteases with cytotoxic activity that are localized in neutrophil primary granules.54 The serprocidin family includes neutrophil elastase, cathepsin G, proteinase 3, and azurocidin/CAP37. The serprocidins are structurally related to the granzymes of cytotoxic T cells and manifest microbicidal activity both via direct membrane perturbation as well as by proteolytic action. Whereas elastase and cathepsin G are catalytically active, the divergent primary structure of azurocidin in the region corresponding to the active site render it enzymatically inactive.55 Nonenzymatic killing by serprocidins is believed to depend on the membrane perturbing effects of these cationic proteins. Serprocidins manifest broad cytotoxic activity against gram-negative (eg, E coli) and gram-positive bacteria (Streptococcus faecalis), fungi (Candida albicans), and protozoa as well as mammalian cells.54 Azurocidin acts in synergy with either elastase or cathepsin G to kill the bacterium Capnocytophaga sputigena.56 Elastase also participates in generating antimicrobial activity during inflammatory responses by cleaving cathelicidin proforms (see below) to generate active antimicrobial peptides.57 Of note, mice rendered deficient in neutrophil elastase by genetic engineering are more susceptible to sepsis and death despite normal accumulation of leukocytes, suggesting an impairment in bacterial killing.58 Unlike most of the other cationic proteins and peptides, azurocidin actually enhances cellular responses to endotoxin by a mechanism that has yet to be defined.59 Cathelicidins.
The cathelicidins are a structurally diverse group of antimicrobial
peptides that are expressed at the C-terminus of 11- to 20-kd inactive
proforms in the neutrophil secondary granules of humans and other
mammalian species.60 Because neutrophil secondary granules
are readily degranulated to the extracellular space, cathelicidins are
released into inflammatory fluids where they are found at relatively
high concentrations.49 Some cathelicidin genes possess
upstream DNA motifs (eg, NF- Lysozyme. Lysozyme is a 14-kd enzyme that degrades bacterial peptidoglycans by cleaving the glycosidic bond of N-acetyl glucosamine. This enzyme is stored in both primary and secondary neutrophil granules. Gram-positive bacteria with minimally cross-linked peptidoglycan (eg, Bacillus subtilis) allow access of lysozyme to its substrate, are rapidly lysed and killed by this enzyme, and are generally (consequently?) nonpathogenic. Most gram-positive clinical pathogens possess highly cross-linked peptidoglycan and are thereby resistant to the action of lysozyme. Moreover, gram-negative bacteria are generally resistant to the action of lysozyme by virtue of their hydrophobic outer membrane. The spectrum of action of native lysozyme may be broadened by synergistic action with other antibiotic proteins of neutrophils including lactoferrin70 and defensins.71 Use of recombinant DNA technology to create a novel lysozyme congener possessing a hydrophobic N-terminal peptide enhances activity against gram-negative bacteria.72 Transgenic expression of human lysozyme in mice is associated with production of milk that is antimicrobial toward cold spoilage pathogens such as Lactobacillus viscus.73 Phospholipases A2.
The 14-kd phopholipases A2 (PLA2) are
disulfide-rich enzymes that hydrolyze phospholipids at the 2-acyl
position. Group II PLA2, which are structurally defined by
a unique disulfide arrangement, are found in neutrophil granules and
are also secreted by the liver into plasma as acute-phase
reactants.18 Neutrophil-derived antibiotics such as BPI
and certain cathelicidins (eg, rabbit p15s) can render the membrane
phospholipids of E coli susceptible to
PLA2-mediated enzymatic cleavage.74 The degree
of destruction of gram-negative bacteria ingested by neutrophils is
related to the magnitude of phospholipolysis.75 More
recent work has focused on the potent (nmol/L) and selective direct
bactericidal action of PLA2 against gram-positive bacteria
including Staphylococcus aureus, Listeria
monocytogenes, and vancomycin-resistant Enterococcus. PLA2 is found in murine intestinal Paneth cells, rabbit
inflammatory ascitic fluid, human tear fluid,76 and in the
acute-phase plasma of baboons challenged with intravenous
bacteria.27 In all of these settings, PLA2 has
been shown to function enzymatically as the primary microbicide active
against gram-positive bacteria. Consistent with these results, mice
that express PLA2 are relatively protected against S
aureus infection when compared to their PLA2 Calprotectin. The calprotectin complex is composed of 8- and 14-kd members of the S-100 family of calcium-binding proteins and is particularly abundant in the cytosol of neutrophils where it represents about 30% of total cytosolic protein.78 Calprotectin manifests antimicrobial activity in the µmol/L range against bacteria and fungi by zinc chelation that is mediated by histidine-rich protein regions.79 Both neutrophil lysates and abscess fluids possess zinc-reversible antimicrobial activity suggesting that "holocrine secretion" of calprotectin from neutrophils undergoing cell death might represent another mechanism by which these cells combat infection.80 Defensins.
The defensins are a family of 4-kd peptides with broad cytotoxic
activity against bacteria, fungi, parasites, viruses, and host
cells.81 The activity of defensins depends on both their cationicity as well as their 3-dimensional structure.82
Defensins form multimeric voltage-dependent pores that permeabilize
cellular membranes. Whereas classical (  -defensins act at mucosal
surfaces,  -defensins may be most active intracellularly in the phagolysosome.
Of note, a recently described cyclic antimicrobial peptide found in the
neutrophils and monocytes of rhesus macaques is an index member of a
novel family named "theta" ( )-defensins.86 Elegant
biochemical analysis reveals that rhesus -defensin-1 (RTD-1) is
naturally produced by a unique ligation of 2 truncated -defensins.
The cyclic conformation of -defensins confers relative salt
insensitivity allowing this peptide to exert its microbicidal effect in
physiologic saline.
Eosinophils An important role for eosinophils in antiparasitic defense has been suggested by several observations: (1) parasitic infection is associated with marked eosinophilia mediated by IL-5, (2) depletion of eosinophils with selective antisera has been associated with increased pathogen burden in some animal models of parasitic infection,87 and (3) eosinophil-derived cytotoxic proteins demonstrate antiparasitic activity in vitro. Eosinophils also possess antimicrobial activity against bacteria and fungi. Although eosinophils have been shown to have lesser bactericidal activity toward E coli and S aureus than neutrophils, it is not known whether this might relate to relative deficiency of oxygen-dependent (eg, peroxidase-H2O2-Cl system) or oxygen-independent (eg, antimicrobial protein/peptide) mechanisms.88,89Eosinophils contain at least 2 granule populations Eosinophils share certain members of the neutrophil armamentarium. Lysozyme has been localized to eosinophil secondary granules.100 It has been suggested that the presence of relatively low amounts of BPI in the secondary granules of human eosinophils might reflect a role for these cells in antibacterial host defense or a role for BPI in antiparasitic activity.101 Macrophages In addition to oxidase and nitric oxide synthase activity, macrophages also possess oxygen-independent microbicidal activity.102 Macrophages express multiple components of the classic and alternative pathways of the complement system, as well as several of the antimicrobial proteins and peptides described in neutrophils.103 Multiple studies have demonstrated that the enzymes elastase and lysozyme are expressed by activated macrophages. Rabbit pulmonary macrophages express defensin peptides.104 The origin of cell surface BPI expressed on human peripheral blood monocytes remains to be determined.105 The cytosolic calprotectin protein that is abundant in neutrophil cytosol is also found in macrophages.78Studies have attempted to identify antimicrobial proteins and peptides
in macrophages or in macrophage-like cell lines activated by
interferon- Transgenic techniques have been used to enhance the antimicrobial
activity of macrophages. A preliminary effort to enhance intracellular
microbicidal activity by xenogenic expression of the defensin HNP-1 in
murine macrophages enhanced growth inhibition of Histoplasma
capsulatum.108 Macrophages transfected with a BPI-IgG
fusion protein are better equipped to neutralize endotoxin and have
diminished tumor necrosis factor (TNF)-
Both cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells possess granule-associated cytotoxic proteins and peptides that can be directed toward microbial pathogens as well as host cells altered by infection or tumorigenesis. CTLs and NK cells contain perforin, a monomeric pore-forming protein with homology to the C9 component of complement.110 The granzymes are a family of 25- to 30-kd serine proteases found in the granules of cytotoxic T cells that are homologous to the neutrophil-derived serprocidins.111 Granzymes, which are expressed in keratinocytes as well, participate in triggering apoptosis in target host cells and in bactericidal activity.112,113 CTLs and NK cells are also the repository of members of the saposin class of cytotoxic peptides, including porcine NK lysin and human granulysin. NK lysin is an IL-2-inducible 78 amino acid cationic cytotoxic peptide with activity against bacteria (including E coli and Bacillus megaterium) and tumor cells.114 NK lysin possesses 3 intramolecular disulfide bonds that are required for potent cytotoxic activity and whose reduction by host thioredoxin reductase may serve as a means of limiting the cytotoxic effect of this peptide.115 In addition to direct cytotoxic effects, NK lysin is capable of binding and neutralizing LPS.116 Granulysin, a peptide of CTL granules, is a broad-spectrum microbicide that is required for intracellular killing of Mycobacterium tuberculosis.117
Although principally thought to have a role in hemostasis and wound healing, platelets are increasingly appreciated as antimicrobial effectors.118 From an evolutionary perspective, the expression of coagulation, wound healing, and antimicrobial defense by a blood-borne cell is well described in the hemocytes of the horseshoe crab Limulus polyphemus.119 In an animal model of Streptococcus sanguis endocarditis, rabbits rendered thrombocytopenic by administration of antiplatelet serum developed a higher bacterial burden at aortic valve vegetations, suggesting an antimicrobial role for platelets.120 Over the past decade, work by Yeaman and colleagues121,122
has demonstrated that platelet Pathogenic strains of S aureus and S epidermidis derived from patients with endocarditis are often resistant to tPMP, raising the possibility that such resistance might be an important virulence factor in such infections.124
The effort to develop blood cell-derived proteins and peptides as novel antibiotics is driven by at least 2 considerations: (1) the rising prevalence of multidrug-resistant microorganisms, and (2) a growing population of immunocompromised patients. In terms of immunocompromised patients, clinical conditions associated with impaired leukocyte or platelet function include newborn status, overwhelming sepsis, leukemia, exposure to chemotherapy, congenital hematopoietic defects, and cystic fibrosis.125 However, the ability to enhance hematopoietic cell defense has been limited. Granulocyte transfusions are associated with potential side effects, including alloimmune reactions126 and induction of pulmonary inflammation. Administration of the cytokines such as granulocyte colony-stimulating factor and GM-CSF has been shown to raise neutrophil counts in patients undergoing chemotherapy but has not demonstrated improved survival or clinical outcome.127 Whether the leukocytes generated by the administration of such growth factors are fully functional and contain all of the aforementioned antimicrobial apparatus has not been fully defined. Thus, considerations relating to both microbe and host have generated considerable enthusiasm for evaluating host-derived antimicrobial proteins and peptides as potential novel antibiotics. Topical/aerosol formulations The magainin peptides derived from frog skin were the first of the animal-derived antimicrobial peptides to reach clinical trial. Phase III evaluation of a topical magainin preparation for treatment of impetigo and polymicrobial infections characteristic of ulcers in patients with diabetes128 reportedly demonstrated insufficient activity. The wide variety of insect-derived antimicrobial peptides (Table 1) are currently in early stages of development as potential novel antibiotics.129The porcine neutrophil-derived peptide protegrin (Figure 2B) is the first of the mammalian cathelicidin peptides to reach clinical trial. Topical administration of protegrin in a hamster model of chemotherapy-induced oral mucositis was associated with decreased microbial burden at mucosal lesions, decreased lesion severity, and accelerated recovery.130 A phase I study demonstrated that this peptide can be safely delivered topically to humans who develop mucositis in the context of myeloablative chemotherapy. A recently completed phase II study of topical (oral) protegrin involving 177 patients undergoing bone marrow transplantation indicated that administration of this peptide is associated with a statistically significant reduction in mucositis after transplantation and a trend toward a reduced number of febrile days.131 A phase III study of protegrin for the prevention of mucositis associated with myeloablative chemotherapy is now underway. Protegrin is also being evaluated as an aerosolized antimicrobial therapy for the chronic respiratory infections of patients with cystic fibrosis. Systemic administration The selective action of BPI (Figure 2A) toward gram-negative bacteria and their endotoxin, which has been documented in vitro, has recently been demonstrated in animal models and in humans as well. A recombinant 21-kd N-terminal modified fragment (rBPI21) of human BPI expresses both the antibacterial and anti-endotoxic activities of the holoprotein and has demonstrated beneficial effects, either alone or in synergistic combination with conventional antibiotics, in animal models of sepsis, pneumonia, endotoxemia, and burns.48 Phase I studies in humans indicate that rBPI21 is well tolerated and nonimmunogenic. rBPI23 (another recombinant N-terminal fragment of BPI) given intravenously to subjects who have received endotoxin is able to markedly inhibit LPS-induced cytokine release,132 coagulant responses, and pathophysiologic changes such as alteration of cardiac index.133Several potential indications for rBPI21 have been selected for phase II studies, based on the presence of gram-negative bacteria or endotoxemia or both: (1) meningococcemia and intra-abdominal infections (endotoxin on or released from invading bacteria), (2) hemorrhagic trauma (endotoxin translocation secondary to decreased intestinal barrier integrity), and (3) liver resection (decreased endotoxin clearance). A phase II study demonstrated that open-label administration of rBPI21 to 26 children with fulminant meningococcemia, admitted to a pediatric intensive care unit, was associated with reduced mortality relative to that predicted by clinical prognostic scores, IL-6 levels, and historical control.134 Two phase III double-blinded placebo-controlled trials of rBPI21 for the treatment of hemorrhagic trauma and of fulminant meningococcemia have been completed recently. Although the former trial was stopped due to insufficient activity, the treatment group in the meningococcemia study reportedly had lower rates of mortality and morbidity. Results of this study are currently under evaluation. Potential future indications for rBPI21 may include
conditions characterized by a relative deficiency of endogenous BPI.
Newborns are relatively deficient in BPI by virtue of the relatively
low amounts of BPI protein in their neutrophils135 as well
as their well known tendency for leukopenia in the face of overwhelming sepsis. Supplementation of newborn cord blood with rBPI21
enhances its antibacterial activity against certain gram-negative
clinical pathogens and inhibits release of TNF- It is likely that additional leukocyte- and platelet-derived antibiotics will reach clinical trial as systemic agents. The peptide protegrin reduces mortality of leukopenic mice injected with vancomycin-resistant Enterococcus faecium65 and a peptide derived from CAP18 reduces cytokine release and mortality when administered with aztreonam in a mouse model of Pseudomonas aeruginosa infection.137 Adenovirus-mediated gene transfer of the human cathelicidin peptide LL-37/hCAP-18 was found to restore bacterial killing in a cystic fibrosis xenograft model,138 raising the possibility that enhancing such innate immune mechanisms might someday be of clinical benefit.
The growing problem of microbial resistance has placed increasing emphasis on developing novel antibiotics. Moreover, a growing number of patients have impaired leukocyte- or platelet-mediated defense either due to their primary disease or its treatment. Blood-derived antibiotic proteins and peptides represent a source of innate defense molecules that target the microbial membrane leading to growth arrest and in some instances, neutralization of proinflammatory surface components (eg, LPS). These natural antibiotics and their synthetic congeners have activity that can be demonstrated in biologic fluids and animal models and have proven safe in preliminary clinical trials. Judicious enhancement of this arm of innate immunity may eventually prove of clinical benefit to selected patients.
The advice and support of Drs Philip Pizzo and Donald Goldmann are gratefully appreciated.
Submitted January 17, 2000; accepted May 4, 2000.
Supported by the Medical Scientist Training Program, as part of National Institutes of Health Training Grant 5T32GM07308 from the National Institute of General Medical Science; NIH/National Center for Research Resources/ General Clinical Research Center Grant M01RR02172, The Children's Hospital of Boston; an American Academy of Pediatrics Resident Research Award; The Dana Farber Cancer Research Institute; and by a grant from XOMA (US) LLC.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Ofer Levy, Division of Infectious Disease, The Children's Hospital, 300 Longwood Ave, Boston, MA 02115; e-mail: levy_o{at}a1.tch.harvard.edu.
1.
Hoffman J, Kafatos F, Janeway C, Ezekowitz R.
Phylogenetic perspectives in innate immunity.
Science.
1999;284:1313-1318
2.
Babior B.
NADPH oxidase: an update.
Blood.
1999;93:1464-1476
3.
Hampton M, Kettle A, Winterbourn C.
Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing.
Blood.
1998;92:3007-3017 4. Meischl C, Roos D. The molecular basis of chronic granulomatous disease. Springer Semin Immunopathol. 1998;19:417-434[Medline] [Order article via Infotrieve]. 5. MacMicking J, Xie Q, Nathan C. Nitric oxide and macrophage function. Ann Rev Immunol. 1997;15:323-350[Medline] [Order article via Infotrieve]. 6. Wheeler MA, Smith SD, Garcia-Cardena G, et al. Bacterial infection induces nitric oxide synthase in human neutrophils. J Clin Invest. 1997;99:110-116[Medline] [Order article via Infotrieve]. 7. Govoni G, Gros P. Macrophage NRAMP1 and its role in resistance to microbial infections. Inflamm Res. 1998;47:277-284[Medline] [Order article via Infotrieve].
8.
Hackam D, Rotstein O, Zhang W, et al.
Host resistance to intracellular infection: mutation of natural resistance-associated macrophage protein 1 (Nramp1) impairs phagosomal acidification.
J Exp Med.
1998;188:351-364 9. Skamene E, Schurr E, Gros P. Infection genomics: Nramp1 as a major determinant of natural resistance to intracellular infections. Ann Rev Med. 1998;49:275-287[Medline] [Order article via Infotrieve]. 10. Weiss J, Kao L, Victor M, Elsbach P. Oxygen-independent intracellular and oxygen-dependent extracellular killing of Escherichia coli S15 by human polymorphonuclear leukocytes. J Clin Invest. 1985;76:206-212. 11. Hirsch J. Phagocytin: a bactericidal substance from polymorphonuclear leukocytes. J Exp Med. 1956;103:589-621[Abstract]. 12. Levy O. Antibiotic proteins of polymorphonuclear leukocytes. Eur J Haematol. 1996;56:263-277[Medline] [Order article via Infotrieve]. 13. Marra MN, Wilde CG, Griffith JE, Snable JL, Scott RW. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol. 1990;144:662-666[Abstract].
14.
Scott M, Gold M, Hancock R.
Interaction of cationic peptides with lipoteichoic acid and gram-positive bacteria.
Infect Immun.
1999;67:6445-6453
15.
Scott M, Vreugdenhil A, Buurman W, Hancock R, Gold M.
Cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein.
J Immunol.
2000;164:549-553 16. Matsuzaki K, Sugishita K, Fujii N, Miyajima K. Molecular basis for membrane selectivity of an antimicrobial peptide, magainin 2. Biochemistry. 1995;34:3423-3429[Medline] [Order article via Infotrieve]. 17. White SH, Wimley WC, Selsted ME. Structure, function, and membrane integration of defensins. Curr Opin Struct Biol. 1995;5:521-527[Medline] [Order article via Infotrieve]. 18. Ganz T, Weiss J. Antimicrobial peptides of phagocytes and epithelia. Semin Hematol. 1997;34:343-354[Medline] [Order article via Infotrieve]. 19. Hoffmann JA. Innate immunity of insects. Curr Opin Immunol. 1995;7:4-10[Medline] [Order article via Infotrieve]. 20. Hoffmann JA, Reichhart JM, Hetru C. Innate immunity in higher insects. Curr Opin Immunol. 1996;8:8-13[Medline] [Order article via Infotrieve]. 21. Bulet P, Hetru C, Dimarcq JL, Hoffmann D. Antimicrobial peptides in insects; structure and function. Dev Comp Immunol. 1999;23:329-344[Medline] [Order article via Infotrieve].
22.
Modlin R, Brightbill H, Godowski P.
The toll of innate immunity on microbial pathogens.
N Engl J Med.
1999;340:1834-1835 23. Boman HG. Peptide antibiotics and their role in innate immunity. Ann Rev Immunol. 1995;13:61-92[Medline] [Order article via Infotrieve]. 24. García-Olmedo F, Molina A, Alamillo JM, Rodríguez-Palenzuéla P. Plant defense peptides. Biopolymers. 1998;47:479-491[Medline] [Order article via Infotrieve]. 25. Anderson M, Zasloff M. Antimicrobial peptides: complementing classical inflammatory mechanisms of defense. In: Gallin J,Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. Philadelphia: Lippincott Williams & Wilkins; 1999:1279-1292.
26.
Schonwetter BS, Stolzenberg ED, Zasloff MA.
Epithelial antibiotics induced at sites of inflammation.
Science.
1995;267:1645-1648 27. Weinrauch Y, Abad C, Liang NS, Lowry SF, Weiss J. Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. Role of group IIA phospholipase A2. J Clin Invest. 1998;102:633-638[Medline] [Order article via Infotrieve]. 28. Dinauer M. The phagocyte system and disorders of granulopoiesis and granulocyte function. In: Nathan D,Orkin S, eds. Hematology of Infancy and Childhood. Philadelphia: WB Saunders; 1998:889-967.
29.
Borregaard N, Cowland J.
Granules of the human neutrophilic polymorphonuclear leukocyte.
Blood.
1997;89:3503-3521 30. Lehrer R. Holocrine secretion of calprotectin: a neutrophil-mediated defense against C. albicans? J Lab Clin Med. 1993;121:235-243[Medline] [Order article via Infotrieve].
31.
Anderson B, Baker H, Dodson E.
Stucture of human lactoferrin at 3.2 angstrom resolution.
Proc Natl Acad Sci U S A.
1987;84:1769-1773 32. Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis. 1997;25:888-895[Medline] [Order article via Infotrieve].
33.
Chapple DS, Mason DJ, Joannou CL, et al.
Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against Escherichia coli serotype O111.
Infect Immun.
1998;66:2434-2440 34. Kuwata H, Yip TT, Yip CL, Tomita M, Hutchens TW. Bactericidal domain of lactoferrin: detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry. Biochem Biophys Res Commun. 1998;245:764-773[Medline] [Order article via Infotrieve]. 35. Harmsen MC, Swart PJ, de Bethune MP, et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro [see comments]. J Infect Dis. 1995;172:380-388[Medline] [Order article via Infotrieve].
36.
Elass-Rochard E, Legrand D, Salmon V, et al.
Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein.
Infect Immun.
1998;66:486-491 37. Tobias P, Tapping R, Gegner J. Endotoxin interactions with lipopolysaccharide-responsive cells. Clin Infect Dis. 1999;28:476-481[Medline] [Order article via Infotrieve].
38.
Lee WJ, Farmer JL, Hilty M, Kim YB.
The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets.
Infect Immun.
1998;66:1421-1426 39. Elsbach P, Weiss J. Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol. 1998;10:45-49[Medline] [Order article via Infotrieve].
40.
Beamer LJ, Carroll SF, Eisenberg D.
Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution.
Science.
1997;276:1861-1864
41.
Iovine NM, Elsbach P, Weiss J.
An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains.
Proc Natl Acad Sci U S A.
1997;94:10973-10978 42. Levy O, Sisson R, Kenyon J, et al. Enhancement of neonatal innate defense: effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein (rBPI21) on growth and TNF-inducing activity of Gram-negative bacteria tested in neonatal cord blood ex vivo.Infect Immun. In press.
43.
Gazzano-Santoro H, Parent JB, Grinna L, et al.
High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide.
Infect Immun.
1992;60:4754-4761 44. Wiese A, Brandenburg K, Carroll SF, Rietschel ET, Seydel U. Mechanisms of action of bactericidal/permeability-increasing protein BPI on reconstituted outer membranes of gram-negative bacteria. Biochemistry. 1997;36:10311-10319[Medline] [Order article via Infotrieve]. 45. Wiese A, Brandenburg K, Lindner B, et al. Mechanisms of action of the bactericidal/permeability-increasing protein BPI on endotoxin and phospholipid monolayers and aggregates. Biochemistry. 1997;36:10301-10310[Medline] [Order article via Infotrieve].
46.
Capodici C, Chen S, Sidorczyk Z, Elsbach P, Weiss J.
Effect of lipopolysaccharide (LPS) chain length on interactions of bactericidal/permeability-increasing protein and its bioactive 23-kilodalton NH2-terminal fragment with isolated LPS and intact Proteus mirabilis and Escherichia coli.
Infect Immun.
1994;62:259-265
47.
Horwitz A, Williams R, Liu P, Nadell R.
Bactericidal/permeability-increasing protein inhibits growth of a strain of Acholeplasma laidlawii and L forms of the gram-positive bacteria Staphyloccus aureus and Streptococcus pyogenes.
Antimicrob Agents Chemother.
1999;43:2314-2316 48. Elsbach P. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J Leukoc Biol. 1998;64:14-18[Abstract]. 49. Weinrauch Y, Foreman A, Shu C, et al. Extracellular accumulation of potently microbicidal bactericidal/permeability-increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exudate. J Clin Invest. 1995;95:1916-1924. 50. Weiss J, Elsbach P, Shu C, et al. Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest. 1992;90:1122-1130. 51. Fenton MJ, Golenbock DT. LPS-binding proteins and receptors. J Leukoc Biol. 1998;64:25-32[Abstract].
52.
Tobias PS, Soldau K, Iovine NM, Elsbach P, Weiss J.
Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS.
J Biol Chem.
1997;272:18682-18685 53. Levy O, Ooi CE, Elsbach P, et al. Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins. J Immunol. 1995;154:5403-5410[Abstract]. 54. Gabay J, Almeida R. Antibiotic peptides and serine protease homologs in human polymorphonuclear leukocytes: defensins and azurocidin. Curr Opin Immunol. 1993;5:97-102[Medline] [Order article via Infotrieve]. 55. Campanelli D, Detmers PA, Nathan CF, Gabay JE. Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties. J Clin Invest. 1990;85:904-915.
56.
Miyasaki KT, Bodeau AL.
Human neutrophil azurocidin synergizes with leukocyte elastase and cathepsin G in the killing of Capnocytophaga sputigena.
Infect Immun.
1992;60:4973-4975
57.
Shi J, Ganz T.
The role of protegrins and other elastase-activated polypeptides in the bactericidal properties of porcine inflammatory fluids.
Infect Immun.
1998;66:3611-3617 58. Belaaouaj A, McCarthy R, Baumann M, et al. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med. 1998;4:615-618[Medline] [Order article via Infotrieve].
59.
Heinzelmann M, Mercer-Jones MA, Flodgaard H, Miller FN.
Heparin-binding protein (CAP37) is internalized in monocytes and increases LPS-induced monocyte activation.
J Immunol.
1998;160:5530-5536 60. Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 1995;374:1-5[Medline] [Order article via Infotrieve].
61.
Gudmundsson GH, Magnusson KP, Chowdhary BP, et al.
Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene family member: comparative mapping of the locus for the human peptide antibiotic FALL-39.
Proc Natl Acad Sci U S A.
1995;92:7085-7089 62. Gudmundsson GH, Agerberth B, Odeberg J, et al. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem. 1996;238:325-332[Medline] [Order article via Infotrieve].
63.
Frohm M, Agerberth B, Ahangari G, et al.
The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders.
J Biol Chem.
1997;272:15258-15263
64.
Sorenson O, Bratt T, Johnsen A, Madsen M, Borregaard N.
The human antibacterial cathelicidin, hCAP-18, is bound to lipoproteins in plasma.
J Biol Chem.
1999;274:22445-22451 65. Steinberg DA, Hurst MA, Fujii CA, et al. Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob Agents Chemother. 1997;41:1738-1742[Abstract]. 66. Roumestand C, Louis V, Aumelas A, et al. Oligomerization of protegrin-1 in the presence of DPC micelles. A proton high-resolution NMR study. FEBS Lett. 1998;421:263-267[Medline] [Order article via Infotrieve]. 67. Hirata M, Zhong J, Wright SC, Larrick JW. Structure and functions of endotoxin-binding peptides derived from CAP18. Prog Clin Biol Res. 1995;392:317-326[Medline] [Order article via Infotrieve].
68.
Zarember K, Elsbach P, Shin-Kim K, Weiss J.
p15s (15-kD antimicrobial proteins) are stored in the secondary granules of rabbit granulocytes: implications for antibacterial synergy with the bactericidal/permeability-increasing protein in inflammatory fluids.
Blood.
1997;89:672-679 69. Falla TJ, Hancock RE. Improved activity of a synthetic indolicidin analog. Antimicrob Agents Chemother. 1997;41:771-775[Abstract].
70.
Leitch EC, Willcox MD.
Synergic antistaphylococcal properties of lactoferrin and lysozyme.
J Med Microbiol.
1998;47:837-842 71. Bals R, Wang X, Wu Z, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest. 1998;102:874-880[Medline] [Order article via Infotrieve]. 72. Arima H, Ibrahim HR, Kinoshita T, Kato A. Bactericidal action of lysozymes attached with various sizes of hydrophobic peptides to the C-terminal using genetic modification. FEBS Lett. 1997;415:114-118[Medline] [Order article via Infotrieve]. 73. Maga EA, Anderson GB, Cullor JS, Smith W, Murray JD. Antimicrobial properties of human lysozyme transgenic mouse milk. J Food Prot. 1998;61:52-56[Medline] [Order article via Infotrieve]. 74. Levy O, Ooi CE, Weiss J, Lehrer RI, Elsbach P. Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. J Clin Invest. 1994;94:672-682. 75. Wright GC, Weiss J, Kim KS, Verheij H, Elsbach P. Bacterial phospholipid hydrolysis enhances the destruction of Escherichia coli ingested by rabbit neutrophils. Role of cellular and extracellular phospholipases. J Clin Invest. 1990;85:1925-1935.
76.
Qu XD, Lehrer RI.
Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears.
Infect Immun.
1998;66:2791-2797
77.
Laine V, Grass D, Nevalainen T.
Protection by group II phospholipase A2 against S. aureus.
J Immunol.
1999;162:7402-7408 78. Hessian PA, Edgeworth J, Hogg N. MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes. J Leukoc Biol. 1993;53:197-204[Abstract]. 79. Loomans HJ, Hahn BL, Li QQ, Phadnis SH, Sohnle PG. Histidine-based zinc-binding sequences and the antimicrobial activity of calprotectin. J Infect Dis. 1998;177:812-814[Medline] [Order article via Infotrieve]. 80. Sohnle PG, Collins-Lech C, Wiessner JH. The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants. J Infect Dis. 1991;164:137-142[Medline] [Order article via Infotrieve]. 81. Martin E, Ganz T, Lehrer R. Defensins and other endogenous peptide antibiotics of vertebrates. J Leukoc Biol. 1995;58:128-136[Abstract].
82.
Hill C, Yee J, Selsted M, Eisenberg D.
Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization.
Science.
1991;251:1481-1485 83. Valore EV, Park CH, Quayle AJ, et al. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest. 1998;101:1633-1642[Medline] [Order article via Infotrieve].
84.
Goldman MJ, Anderson GM, Stolzenberg ED, et al.
Human 85. Knowles MR, Robinson JM, Wood RE, et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects [published erratum appears in J Clin Invest. 1998;101:285]. J Clin Invest. 1997;100:2588-2595[Medline] [Order article via Infotrieve].
86.
Tang Y, Yuan J, Osapay G, et al.
A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated 87. Rosenberg H. Eosinophils. In: Gallin J,Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. Philadelphia: Lippincott Williams & Wilkins; 1999:61-76.
88.
DeChatelet LR, Migler RA, Shirley PS, et al.
Comparison of intracellular bactericidal activities of human neutrophils and eosinophils.
Blood.
1978;52:609-617
89.
Yazdanbakhsh M, Eckmann C, Bot A, Roos D.
Bactericidal action of eosinophils from normal human blood.
Infect Immun.
1986;53:192-198 90. Bainton D. Developmental biology of neutrophils and eosinophils Gallin J, Snyderman R. Inflammation: Basic Principles and Clinical Correlates. Philadelphia: Lippincott Williams & Wilkins; 1999:13-34. 91. Hamann KJ, Gleich GJ, Checkel JL, et al. In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. J Immunol. 1990;144:3166-3173[Abstract].
92.
Butterworth AE, Vadas MA, Wassom DL, et al.
Interactions between human eosinophils and schistosomula of Schistosoma mansoni. II. The mechanism of irreversible eosinophil adherence.
J Exp Med.
1979;150:1456-1471 93. Molina HA, Kierszenbaum F, Hamann KJ, Gleich GJ. Toxic effects produced or mediated by human eosinophil granule components on Trypanosoma cruzi. Am J Trop Med Hyg. 1988;38:327-334. 94. Lehrer RI, Szklarek D, Barton A, et al. Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol. 1989;142:4428-4434[Abstract]. 95. Wagner JM, Franco M, Kephart GM, Gleich GJ. Localization of eosinophil granule major basic protein in paracoccidioidomycosis lesions. Am J Trop Med Hyg. 1998;59:66-72[Abstract].
96.
Plager DA, Loegering DA, Weiler DA, et al.
A novel and highly divergent homolog of human eosinophil granule major basic protein.
J Biol Chem.
1999;274:14464-14473
97.
Rosenberg HF.
Recombinant human eosinophil cationic protein. Ribonuclease activity is not essential for cytotoxicity.
J Biol Chem.
1995;270:7876-7881 98. Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature. 1986;321:613-616[Medline] [Order article via Infotrieve]. 99. Sur S, Glitz DG, Kita H, et al. Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. J Leukoc Biol. 1998;63:715-722[Abstract]. 100. Stirling JW. Ultrastructural localization of lysozyme in human colon eosinophils using the protein A-gold technique: effects of processing on probe distribution. J Histochem Cytochem. 1989;37:709-714[Abstract].
101.
Calafat J, Janssen H, Tool A, et al.
The bactericidal/permeability-increasing protein (BPI) is present in specific granules of human eosinophils.
Blood.
1998;91:4770-4775 102. Murray H, Cartelli D. Killing of intracellular Leishmania donovani by human mononuclear phagocytes. Evidence for oxygen-dependent and -independent leishmanicidal activity. J Clin Invest. 1983;72:32-44. 103. Gordon S. Development and distribution of mononuclear phagocytes. In: Gallin J,Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. Philadelphia: Lippincott Williams & Wilkins; 1999:35-48. 104. Ganz T, Rayner J, Valore E, et al. The structure of the rabbit macrophage defensin genes and their organ-specific expression. J Immunol. 1989;143:1358-1365[Abstract]. 105. Dentener MA, Francot GJ, Buurman WA. Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes. J Infect Dis. 1996;173:252-255[Medline] [Order article via Infotrieve].
106.
Hiemstra PS, Eisenhauer PB, Harwig SS, et al.
Antimicrobial proteins of murine macrophages.
Infect Immun.
1993;61:3038-3046 107. Hiemstra PS, van den Barselaar MT, Roest M, Nibbering PH, van Furth R. Ubiquicidin, a novel murine microbicidal protein present in the cytosolic fraction of macrophages. J Leukoc Biol. 1999;66:423-428[Abstract].
108.
Couto MA, Liu L, Lehrer RI, Ganz T.
Inhibition of intracellular Histoplasma capsulatum replication by murine macrophages that produce human defensin.
Infect Immun.
1994;62:2375-2378
109.
Dahlberg PS, Acton RD, Uknis ME, et al.
Macrophages expressing a fusion protein derived from bactericidal/permeability-increasing protein and IgG are resistant to endotoxin.
Arch Surg.
1996;131:1173-1177 110. Liu CC, Walsh CM, Young JD. Perforin: structure and function. Immunol Today. 1995;16:194-201[Medline] [Order article via Infotrieve]. 111. Pham CT, Ley TJ. The role of granzyme B cluster proteases in cell-mediated cytotoxicity. Semin Immunol. 1997;9:127-133[Medline] [Order article via Infotrieve]. 112. Smyth MJ, O'Connor MD, Trapani JA. Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies. J Leukoc Biol. 1996;60:555-562[Abstract]. 113. Berthou C, Michel L, Soulié A, et al. Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J Immunol. 1997;159:5293-5300[Abstract]. 114. Andersson M, Gunne H, Agerberth B, et al. NK-lysin, a novel effector peptide of cytotoxic T and NK cells. Structure and cDNA cloning of the porcine form, induction by interleukin 2, antibacterial and antitumour activity. EMBO J. 1995;14:1615-1625[Medline] [Order article via Infotrieve].
115.
Andersson M, Holmgren A, Spyrou G.
NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase. Implication for a protective mechanism against NK-lysin cytotoxicity.
J Biol Chem.
1996;271:10116-10120
116.
Andersson M, Girard R, Cazenave P.
Interaction of NK lysin, a peptide produced by cytolytic lymphocytes, with endotoxin.
Infect Immun.
1999;67:201-205
117.
Stenger S, Hanson DA, Teitelbaum R, et al.
An antimicrobial activity of cytolytic T cells mediated by granulysin.
Science.
1998;282:121-125 118. Yeaman MR. The role of platelets in antimicrobial host defense. Clin Infect Dis. 1997;25:951-968[Medline] [Order article via Infotrieve]. 119. Muta T, Iwanaga S. The role of hemolymph coagulation in innate immunity. Curr Opin Immunol. 1996;8:41-47[Medline] [Order article via Infotrieve]. 120. Sullam PM, Frank U, Yeaman MR, et al. Effect of thrombocytopenia on the early course of streptococcal endocarditis. J Infect Dis. 1993;168:910-914[Medline] [Order article via Infotrieve].
121.
Yeaman MR, Puentes SM, Norman DC, Bayer AS.
Partial characterization and staphylocidal activity of thrombin-induced platelet microbicidal protein.
Infect Immun.
1992;60:1202-1209
122.
Yeaman MR, Ibrahim AS, Edwards JEJ, Bayer AS, Ghannoum MA.
Thrombin-induced rabbit platelet microbicidal protein is fungicidal in vitro.
Antimicrob Agents Chemother.
1993;37:546-553 123. Yeaman MR, Bayer AS, Koo SP, Foss W, Sullam PM. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J Clin Invest. 1998;101:178-187[Medline] [Order article via Infotrieve].
124.
Wu T, Yeaman MR, Bayer AS.
In vitro resistance to platelet microbicidal protein correlates with endocarditis source among bacteremic staphylococcal and streptococcal isolates.
Antimicrob Agents Chemother.
1994;38:729-732
125.
Tager AM, Wu J, Vermeulen MW.
The effect of chloride concentration on human neutrophil functions: potential relevance to cystic fibrosis.
Am J Respir Cell Mol Biol.
1998;19:643-652 126. Stroncek D. Neutrophil antibodies. Curr Opin Hematol. 1997;4:455-458[Medline] [Order article via Infotrieve].
127.
Hartmann LC, Tschetter LK, Habermann TM, et al.
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia.
N Engl J Med.
1997;336:1776-1780 128. Jacob L, Zasloff M. Potential therapeutic applications of magainins and other antimicrobial agents of animal origin. Ciba Foundation Symp. 1994;186:197-216[Medline] [Order article via Infotrieve].
129.
Casteels P, Romagnolo J, Castle M, et al.
Biodiversity of apidaecin-type peptide antibiotics. Prospects of manipulating the antibacterial spectrum and combating acquired resistance.
J Biol Chem.
1994;269:26107-26115 130. Loury D, Embree J, So W, et al. Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. Oral Surg Oral Med Oral Pathol Oral Radiol Endodon. 1999;87:544-551[Medline] [Order article via Infotrieve]. 131. Vesole D, Fuchs H. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy. New Orleans: LA; 1999, Abstract # 675. 132. von der Mohlen M, van Deventer S, Levi M, et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis. 1995;172:144-151[Medline] [Order article via Infotrieve]. 133. De Winter R, von der Mohlen M, Van Lieshout H, et al. Recombinant endotoxin binding protein (rBPI23) attentuates endotoxin-induced circulatory changes in humans. J Inflamm. 1995;45:193-206[Medline] [Order article via Infotrieve]. 134. Giroir BP, Quint PA, Barton P, et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet. 1997;350:1439-1443[Medline] [Order article via Infotrieve].
135.
Levy O, Martin S, Eichenwald E, et al.
Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein (BPI).
Pediatrics.
1999;104:1327-1333
136.
Cooke K, Hill G, Crawford J, et al.
Tumor necrosis factor-
137.
Sawa T, Kurahashi K, Ohara M, et al.
Evaluation of antimicrobial and lipopolysaccharide-neutralizing effects of a synthetic CAP18 fragment against Pseudomonas aeruginosa in a mouse model.
Antimicrob Agents Chemother.
1998;42:3269-3275 138. Bals R, Weiner D, Meegalla R, Wilson J. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest. 1999;103:1113-1117[Medline] [Order article via Infotrieve]. 139. Maget-Dana R, Ptak M. Penetration of the insect defensin A into phospholipid monolayers and formation of defensin A-lipid complexes. Biophys J. 1997;73:2527-2533[Medline] [Order article via Infotrieve]. 140. Bulet P, Hegy G, Lambert J, et al. Insect immunity. The inducible antibacterial peptide diptericin carries two O-glycans necessary for biological activity. Biochemistry. 1995;34:7394-7400[Medline] [Order article via Infotrieve].
141.
Fehlbaum P, Bulet P, Michaut L, et al.
Insect immunity. Septic injury of Drosophila induces the synthesis of a potent antifungal peptide with sequence homology to plant antifungal peptides.
J Biol Chem.
1994;269:33159-33163
142.
Carlsson A, Nyström T, de Cock H, Bennich H.
Attacin 143. Hultmark D. Insect lysozymes. EXS. 1996;75:87-102[Medline] [Order article via Infotrieve].
144.
Castle M, Nazarian A, Yi S, Tempst P.
Lethal effect apidaecin on Escherichia coli involve sequential molecular interactions with diverse targets.
J Biol Chem.
1999;274:32555-32564 145. Amiche M, Seon AA, Pierre TN, Nicolas P. The dermaseptin precursors: a protein family with a common preproregion and a variable C-terminal antimicrobial domain. FEBS Lett. 1999;456:352-356[Medline] [Order article via Infotrieve].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. Samant, F.-F. Hsu, A. A. Neyfakh, and H. Lee The Bacillus anthracis Protein MprF Is Required for Synthesis of Lysylphosphatidylglycerols and for Resistance to Cationic Antimicrobial Peptides J. Bacteriol., February 15, 2009; 191(4): 1311 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Haworth and B. D. Levy Endogenous lipid mediators in the resolution of airway inflammation Eur. Respir. J., November 1, 2007; 30(5): 980 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Jang, S.-C. Lee, Y. S. Lee, Y. P. Shin, K. H. Shin, B. H. Sung, B. S. Kim, S. H. Lee, and I. H. Lee Antimicrobial Effect of Halocidin-Derived Peptide in a Mouse Model of Listeria Infection Antimicrob. Agents Chemother., November 1, 2007; 51(11): 4148 - 4156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tsuji, B. Battsetseg, D. Boldbaatar, T. Miyoshi, X. Xuan, J. H. Oliver Jr., and K. Fujisaki Babesial Vector Tick Defensin against Babesia sp. Parasites Infect. Immun., July 1, 2007; 75(7): 3633 - 3640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Radzishevsky, M. Krugliak, H. Ginsburg, and A. Mor Antiplasmodial Activity of Lauryl-Lysine Oligomers Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1753 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. E. Lopez, P. A. Vincent, A. M. Zenoff, R. A. Salomon, and R. N. Farias Efficacy of microcin J25 in biomatrices and in a mouse model of Salmonella infection J. Antimicrob. Chemother., April 1, 2007; 59(4): 676 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. S. Kwakman, A. A. te Velde, C. M. J. E. Vandenbroucke-Grauls, S. J. H. van Deventer, and S. A. J. Zaat Treatment and Prevention of Staphylococcus epidermidis Experimental Biomaterial-Associated Infection by Bactericidal Peptide 2 Antimicrob. Agents Chemother., December 1, 2006; 50(12): 3977 - 3983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Okuda, S. Yomogida, H. Tamura, and I. Nagaoka Determination of the Antibacterial and Lipopolysaccharide-Neutralizing Regions of Guinea Pig Neutrophil Cathelicidin Peptide CAP11. Antimicrob. Agents Chemother., August 1, 2006; 50(8): 2602 - 2607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lukasiewicz, T. Niedziela, W. Jachymek, L. Kenne, and C. Lugowski Structure of the lipid A-inner core region and biological activity of Plesiomonas shigelloides O54 (strain CNCTC 113/92) lipopolysaccharide Glycobiology, June 1, 2006; 16(6): 538 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Cho, I. P. Fraser, K. Fukase, S. Kusumoto, Y. Fujimoto, G. L. Stahl, and R. A. B. Ezekowitz Human peptidoglycan recognition protein S is an effector of neutrophil-mediated innate immunity Blood, October 1, 2005; 106(7): 2551 - 2558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Radzishevsky, S. Rotem, F. Zaknoon, L. Gaidukov, A. Dagan, and A. Mor Effects of Acyl versus Aminoacyl Conjugation on the Properties of Antimicrobial Peptides Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2412 - 2420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lennartsson, K. Pieters, K. Vidovic, and U. Gullberg A murine antibacterial ortholog to human bactericidal/permeability-increasing protein (BPI) is expressed in testis, epididymis, and bone marrow J. Leukoc. Biol., March 1, 2005; 77(3): 369 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Levy Antimicrobial proteins and peptides: anti-infective molecules of mammalian leukocytes J. Leukoc. Biol., November 1, 2004; 76(5): 909 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Balaban, Y. Gov, A. Giacometti, O. Cirioni, R. Ghiselli, F. Mocchegiani, F. Orlando, G. D'Amato, V. Saba, G. Scalise, et al. A Chimeric Peptide Composed of a Dermaseptin Derivative and an RNA III-Inhibiting Peptide Prevents Graft-Associated Infections by Antibiotic-Resistant Staphylococci Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2544 - 2550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ohgami, I. B. Ilieva, K. Shiratori, E. Isogai, K. Yoshida, S. Kotake, T. Nishida, N. Mizuki, and S. Ohno Effect of Human Cationic Antimicrobial Protein 18 Peptide on Endotoxin-Induced Uveitis in Rats Invest. Ophthalmol. Vis. Sci., October 1, 2003; 44(10): 4412 - 4418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Yeaman, K. D. Gank, A. S. Bayer, and E. P. Brass Synthetic Peptides That Exert Antimicrobial Activities in Whole Blood and Blood-Derived Matrices Antimicrob. Agents Chemother., December 1, 2002; 46(12): 3883 - 3891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Nagaoka, S. Hirota, F. Niyonsaba, M. Hirata, Y. Adachi, H. Tamura, S. Tanaka, and D. Heumann Augmentation of the Lipopolysaccharide-Neutralizing Activities of Human Cathelicidin CAP18/LL-37-Derived Antimicrobial Peptides by Replacement with Hydrophobic and Cationic Amino Acid Residues Clin. Vaccine Immunol., September 1, 2002; 9(5): 972 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. McCabe, T. Cukierman, and J. E. Gabay Basic Residues in Azurocidin/HBP Contribute to Both Heparin Binding and Antimicrobial Activity J. Biol. Chem., July 19, 2002; 277(30): 27477 - 27488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Efron, A. Dagan, L. Gaidukov, H. Ginsburg, and A. Mor Direct Interaction of Dermaseptin S4 Aminoheptanoyl Derivative with Intraerythrocytic Malaria Parasite Leading to Increased Specific Antiparasitic Activity in Culture J. Biol. Chem., June 28, 2002; 277(27): 24067 - 24072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kustanovich, D. E. Shalev, M. Mikhlin, L. Gaidukov, and A. Mor Structural Requirements for Potent Versus Selective Cytotoxicity for Antimicrobial Dermaseptin S4 Derivatives J. Biol. Chem., May 3, 2002; 277(19): 16941 - 16951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dagan, L. Efron, L. Gaidukov, A. Mor, and H. Ginsburg In Vitro Antiplasmodium Effects of Dermaseptin S4 Derivatives Antimicrob. Agents Chemother., April 1, 2002; 46(4): 1059 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Canny, O. Levy, G. T. Furuta, S. Narravula-Alipati, R. B. Sisson, C. N. Serhan, and S. P. Colgan Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia PNAS, March 19, 2002; 99(6): 3902 - 3907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Navon-Venezia, R. Feder, L. Gaidukov, Y. Carmeli, and A. Mor Antibacterial Properties of Dermaseptin S4 Derivatives with In Vivo Activity Antimicrob. Agents Chemother., March 1, 2002; 46(3): 689 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jankowski, C. C. Scott, and S. Grinstein Determinants of the Phagosomal pH in Neutrophils J. Biol. Chem., February 15, 2002; 277(8): 6059 - 6066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Nagaoka, S. Hirota, F. Niyonsaba, M. Hirata, Y. Adachi, H. Tamura, and D. Heumann Cathelicidin Family of Antibacterial Peptides CAP18 and CAP11 Inhibit the Expression of TNF-{alpha} by Blocking the Binding of LPS to CD14+ Cells J. Immunol., September 15, 2001; 167(6): 3329 - 3338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ginsburg Cationic peptides from leukocytes might kill bacteria by activating their autolytic enzymes causing bacteriolysis: why are publications proposing this concept never acknowledged? Blood, April 15, 2001; 97(8): 2530 - 2532. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
microbicidal agents that have
long been used as commercial and household
antimicrobials.
B
transcription factors, and NF-
/
, which enhances macrophage microbicidal activity. Several cationic murine microbicidal proteins (MUMPS), which are members of the cationic histone family, have been isolated from macrophages.